Current guidelines recommend testing for RET rearrangements in eligible patients with metastatic NSCLC, based on a clinical trial that led to the FDA approvals of selective RET inhibitors selpercatinib and pralsetinib [113,114]. Here, RET is linked to non-small cell lung carcinoma.